Humanigen Inc (HGENQ)

[cowtown jay]

bluebird bio

This is another small biotech that has an OS and MC very similar to HGEN.

Like HGEN, it is a holding of XBI and ProShares UltraPro Russell2000 (URTY).

https://www.etf.com/stock/BLUE

https://www.etf.com/stock/HGEN

Both BLUE and HGEN hit 52 week lows Friday.

Both BLUE and HGEN have publishings in distinguished journals.

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00494-X/fulltext

https://www.nejm.org/doi/full/10.1056/NEJMoa2113206

Both BLUE and HGEN have Phase III trials in process.

https://clinicaltrials.gov/ct2/show/NCT02906202?term=NCT02906202&draw=2&rank=1

https://clinicaltrials.gov/ct2/results?cond=&term=lenzilumab&cntry=&state=&city=&dist=

Both BLUE and HGEN are developers of cancer-fighting antibodies that are poised to rock Big Pharma's world (complimentary, but non-competitive, from what I see).

https://www.barrons.com/articles/gene-therapy-bluebird-bio-51639260503?siteid=yhoof2

Q1Cam Durrant and BLUE's CEO, Andrew Obenshain, know what they have, and they have the grit to stand up for shareholders against regulators.

Obenshain (linked above):

"The company previously got approval in Europe for its thalassemia gene therapy, but wasn’t able to agree with national health systems there on a price. Unable to afford the price demanded by governments like Germany’s, bluebird withdrew its therapy from the region.

“It was the last thing that we wanted to do,” bluebird Chief Executive Andrew Obenshain told Barron’s. “We tried everything to stay in Europe.” He’s confident that the American healthcare system will pay for bluebird’s gene therapies. The company has been talking with public and private payers here for three years.

“We’ve been through a lot as a company,” said Obenshain. “Now we’re poised to set the standard in gene therapy for decades to come. We have the largest and deepest ex-vivo gene therapy data set, and we’re excited to make it real.”

Durrant, in Lancet peer-review video presentation:

6 min mark. Durrant: "Almost 190K people have died in the United States since FDA received our EUA until now...Lenzilumab could possibly have saved 60-75K of them while we continue to wait for the FDA..."

26 min mark. "...we need immediate and focused attention on potentially life-saving treatments...(to stop) countless lives lost that could potentially have been saved. We call on healthcare professionals, regulatory agencies, policy-makers and patient groups to rectify this neglectful imbalance."

28-30 minutes. Response to Louise Chen

35 minutes. Response to Joe Pantginis. "We do think that the data that were published should be sufficient for EUA...If we're able to deliver 100k patients worth of therapy that will go where both the need is greatest and there is openness to authorizing or approving lenzilumab... So if that happens to be in some other territory than the United States, then we will sell that product in a way that makes sense. And that then will then be down to the regulatory agencies in those countries to explain to their populations why they didn't authorize or approve lenzilumab."


https://event.on24.com/eventRegistration/console/EventConsoleApollo.jsp?&eventid=3546628&sessionid=1&username=&partnerref=&format=fhvideo1&mobile=&flashsupportedmobiledevice=&helpcenter=&key=89B026371EFD46CB1F47B869C82E1992&newConsole=true&nxChe=true&newTabCon=true&consoleEarEventConsole=false&text_language_id=en&playerwidth=748&playerheight=526&eventuserid=497137718&contenttype=A&mediametricsessionid=432612492&mediametricid=4980709&usercd=497137718&mode=launch

For there to be a correlation between an index fund, such as XBI, and for a tiny component of that fund, such as HGEN, there has to be a lot of companies like HGEN that are all being traded with the same algorithm. So that's how this post developed. As soon as I started looking into this concept, I came across BLUE, and was so struck in finding the above, that I put my findings into this post, which I consider as nothing more than work-in-process notes, for a project that I am not convinced that I want to undertake.

Nevertheless, I think it is worth watching the trading activity of BLUE going forward. If anyone is holding BLUE, could you watch that for us when Price Change Parity is signaled between HGEN and CYDY? Since BLUE also hit a 52 week low Friday, I think we could probably find hundreds of companies linked into this algorithm, if we looked into it.